Peginterferon alfa-2b plus ribavirin for chronic hepatitis

Slides:

Advertisements

Similar presentations

Hepatitis web study Hepatitis web study Peginterferon alfa-2a versus Interferon alfa-2a Phase 3 Treatment Naïve, Chronic HCV Zeuzem S, et al. N Engl J.

Advertisements

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV vs. Peginterferon alfa-2a + RBV IDEAL STUDY Phase 3, Treatment Naïve Treatment Naïve,

Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin versus Interferon alfa-2b + Ribavirin Phase 3 Treatment Naïve, Chronic HCV Manns.

Hepatitis web study Hepatitis web study Peginterferon alfa -2a+/- Ribavirin versus Interferon alfa-2b + Ribavirin Phase 3 Treatment Naïve, Chronic HCV.

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin in Blacks & Non-Hispanic Whites Phase 3 Treatment Naïve, Chronic HCV Muir AJ,

Proteasome Inhibition by Fellutamide B Induces Nerve Growth Factor Synthesis John Hines, Michael Groll, Margaret Fahnestock, Craig M. Crews Chemistry &

Hepatitis web study Hepatitis web study Boceprevir with PEG + RBV in Genotype 1 SPRINT-1 Phase 2 Treatment Naïve Kwo PY, et al. Lancet. 2010;376:

Healthy clocks, healthy body, healthy mind Akhilesh B. Reddy, John S. O’Neill Trends in Cell Biology Volume 20, Issue 1, Pages (January 2010) DOI:

Structure of the Hepatitis C Virus IRES Bound to the Human 80S Ribosome: Remodeling of the HCV IRES Daniel Boehringer, Rolf Thermann, Antje Ostareck-Lederer,

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Volume 149, Issue 6, Pages (November 2015)

Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin.

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen? Patrick Marcellin, E. Jenny Heathcote,

Thank God for Richard Dawkins?

Volume 139, Issue 4, Pages (October 2010)

Volume 139, Issue 5, Pages e1 (November 2010)

Mental illness and mental health

Author gender in The Lancet journals

Boceprevir in Treatment Naive SPRINT-2

Pralidoxime for organophosphate poisoning

A twin with Cushing's disease

Volume 149, Issue 6, Pages (November 2015)

Volume 139, Issue 4, Pages (October 2010)

Virological tools to diagnose and monitor hepatitis C virus infection

Volume 143, Issue 3, Pages e5 (September 2012)

Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and Ribavirin Jean–François Rossignol, Asem Elfert,

Boceprevir With Peginterferon Alfa-2a–Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection Steven L. Flamm, Eric Lawitz,

Do air quality alerts benefit public health? New evidence from Canada

Volume 41, Issue 3, Pages (September 2004)

Michael Biermer, Thomas Berg Gastroenterology

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes:

Volume 41, Issue 3, Pages (September 2004)

Volume 155, Issue 5, Pages e2 (November 2018)

Can famine relief meet health and hunger goals simultaneously?

Treatment of hepatitis C

Volume 138, Issue 1, Pages (January 2010)

HIV myths should not be resuscitated

Pesticide self-poisoning: thinking outside the box

Management of cirrhosis due to chronic hepatitis C

Volume 145, Issue 5, Pages e5 (November 2013)

Michael J Goldacre, Jenny J Maisonneuve The Lancet

Volume 138, Issue 7, Pages (June 2010)

Confessions of a journal junkie

Volume 123, Issue 4, Pages (October 2002)

Sven Pischke, Patrick Behrendt, Michael P Manns, Heiner Wedemeyer

Telling it like it isn't: truth and lies in a post-9/11 world

Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease Markus.

Volume 145, Issue 4, Pages e3 (October 2013)

Thank God for Richard Dawkins?

Low-technology approaches

Diagnosis of tuberculous meningitis with invasive pulmonary sampling

Prescription for change

Volume 139, Issue 6, Pages (December 2010)

Volume 143, Issue 3, Pages e5 (September 2012)

Alessio Aghemo, Maria Francesca Donato Gastroenterology

Hepatitis C treatment in patients with kidney disease

This Month in Gastroenterology

Volume 132, Issue 1, Pages (January 2007)

Telaprevir in Treatment Experienced GT-1 PROVE3

Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection Harald Farnik, Christian M. Lange,

Difficulties of surgery in the developing world: a personal view

Interferon alfa-2a for melanoma metastases

Volume 139, Issue 5, Pages (November 2010)

Tapestry of life The Lancet Volume 375, Issue 9723, (April 2010)

Telaprevir + Peginterferon + Ribavirin for GT1 PROVE1 Study

Volume 148, Issue 1, Pages (January 2015)

Induction Pegylated Interferon Alfa-2b in Combination With Ribavirin in Patients With Genotypes 1 and 4 Chronic Hepatitis C: A Prospective, Randomized,

Autism, maths, and sex: the special triangle

Presentation transcript:

Peginterferon alfa-2b plus ribavirin for chronic hepatitis Michael P Manns, John McHutchison, Kenneth Koury, Janice K Albrecht The Lancet Volume 359, Issue 9302, (January 2002) DOI: 10.1016/S0140-6736(02)07431-7 Copyright © 2002 Elsevier Ltd Terms and Conditions

Figure Logistic regression analyses of sustained virological response (SVR) by HCV genotype 1 vs 2 or 3 as a function of ribavirin dose and peginterferon alfa-2b dose PEG=peginterferon. The Lancet 2002 359, DOI: (10.1016/S0140-6736(02)07431-7) Copyright © 2002 Elsevier Ltd Terms and Conditions